– USA, MA – Obsidian Therapeutics, Inc., a clinical-stage biotechnology firm specializing in engineered cell and gene therapies, announced the appointment of Dr. William Pao (M.D., Ph.D.) to its Board as an independent Director.
About Dr. William Pao
Dr. William Pao is renowned for his pioneering research in oncology and extensive leadership in global pharmaceutical development. Maria Fardis, Ph.D., Chair of Obsidian’s Board, expressed enthusiasm about Dr. Pao joining, highlighting his expertise in lung cancer, which will be pivotal as Obsidian expands its OBX-115 development in melanoma and non-small cell lung cancer.
Dr. William Pao holds leadership positions in prestigious medical organizations and co-founded MyCancerGenome, an influential tool in cancer medicine. He earned his degrees from Harvard and Yale University.
About Obsidian Therapeutics
Obsidian’s lead program, OBX-115, is an engineered T-cell therapy designed to enhance antitumor activity through its proprietary cytoDRiVE technology. It is currently under investigation for melanoma and non-small cell lung cancer.
For more information, visit: Obsidian Therapeutics
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.